Aardvark Therapeutics logo
Aardvark Therapeutics
AARD | NASDAQ
Chart Builder DCF Calculator
$1.26
-$0.07 (-5.26%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
-$0.05 (-4.22%)
After-hours: Nov 16, 2026, 7:30 PM ET

Aardvark Therapeutics Company Profile

Company profile explained

Company Profile

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Key Executives

Name Position
Bryan Jones Chief Executive Officer of Ardia
Tien-Li Lee CEO, Secretary & Chairman
Derrick C. Li Chief Business Officer
Dvorit Samid Executive Vice President of Medical Affairs
Justin T. Stege VP and Head of Project Management & Strategy
Manasi Sinha Jaiman Chief Medical Officer
Nelson Sun CFO & COO
Ron Lewis Vice President & Head of CMC
Zhenhuan Zheng Chief Research Officer

Latest SEC Filings

Date Type Title
Oct 23, 2026 8-K Current Report
Oct 22, 2026 8-K Current Report
Oct 08, 2026 4 Filing
Oct 08, 2026 3 Filing
Oct 08, 2026 8-K Current Report
Sep 11, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 21, 2026 4 Filing
View All SEC Filings ➞
Aardvark Therapeutics
Aardvark Therapeutics logo
Country United States
IPO Date Feb 13, 2025
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Tien-Li Lee

Contact Details

4370 La Jolla Village Drive San Diego, California 92122 United States

Stock Details

Ticker Symbol AARD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001774857
CUSIP Number 002942100
ISIN Number US0029421007
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.